Streetbeat News

Products Services

SRRK

Scholar Rock, a biopharmaceutical company, has provided a corporate update for 2024, focusing on its antimyostatin pipeline for treating spinal muscular atrophy (SMA) and cardiometabolic disorders. The company has completed enrollment for its apitegromab Phase 3 SAPPHIRE trial in SMA patients, with topline data expected in Q4 2024. A Phase 2 trial for apitegromab in obesity is set to begin in mid-2024. Scholar Rock will also present new preclinical data on SRK-439, another myostatin inhibitor for obesity, at the Keystone Symposia in February. The company reports having approximately $280 million in cash and cash equivalents and will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:30 pm

BRKR

Bruker Corporation (NASDAQ: BRKR) has acquired Tornado Spectral Systems, a Canadian company known for its Raman instruments used in pharma and biotech quality control. The acquisition aims to enhance Bruker's biopharma process analytical technology (PAT) offerings. Tornado's patented HTVS technology and product line, including the HyperFlux PRO Plus and Process Guardian, are expected to improve Bruker's PAT analyzer range. Financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:26 pm

FDMT

4D Molecular Therapeutics (4DMT) reported clinical pipeline progress, upcoming milestones, and organizational updates. The company remains well-capitalized with $300M in estimated cash, sufficient to fund operations into H1 2026. Key clinical advancements include progress in wet AMD, DME, and CF programs, with Phase 2 trial data for 4D-150 in wet AMD and DME expected in 2024. The company also announced a partnership with Arbor Biotechnologies for CNS diseases and appointed Noriyuki Kasahara as Chief Scientific Officer. Upcoming milestones include data presentations, trial updates, and IND filings across its ophthalmology, pulmonology, cardiology, and rare inherited retinal disorders portfolios.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:20 pm

NKLA

Nikola Corporation reported the production of 42 Class 8 hydrogen fuel cell vehicles and the wholesale of 35 of these vehicles to customers in the US and Canada for the year 2023.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:19 pm

ASMB

GILD

Assembly Biosciences outlined its clinical pipeline milestones for 2024, with four candidates expected in the clinic by year-end, targeting herpesviruses and hepatitis B and D. Initial data from studies on ABI-5366 for genital herpes and ABI-4334 for hepatitis B are due by year-end. The company's antiviral portfolio progress is bolstered by a long-term partnership with Gilead Sciences.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:16 pm

CTMX

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its 2024 priorities, including anticipated milestones for its pipeline. Key programs like CX-904, CX-2051, and CX-801 are expected to reach clinical proof of concept. CX-904, partnered with Amgen, will have Phase 1a data in H2 2024. IND applications for CX-2051 and CX-801 have been filed, with Phase 1 initiations expected in H1 2024. Bristol Myers Squibb is advancing BMS-986288 to Phase 2 studies. CytomX has partnerships with major companies and ended Q3 2023 with $194 million in cash, projecting a runway to H2 2025.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:16 pm

INDP

The European Patent Office has approved a patent for Indaptus Therapeutics' Decoy technology platform, titled 'Methods of Treatment of Infections Using Bacteria'. This patent provides protections for the technology's application in preventing or treating viral infections, alone or in combination with standard care. It is the second patent granted to Indaptus outside the United States for this application.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:14 pm

GOOG

GOOGL

MSFT

Alphabet Inc.'s Google is reportedly preparing to launch a paid version of its AI chatbot, Bard, similar to Microsoft-backed OpenAI's ChatGPT. A cybersecurity enthusiast discovered hidden code on the Bard website indicating a three-month free trial for Google One subscribers, followed by a subscription fee. The code also hints at a new Bard Advanced service powered by Google's AI model, Gemini. The exact details of the subscription tiers are unclear, but the launch seems imminent as promotional content and pricing details are already present in the code.

Portfolio Pulse from Rounak Jain

January 04, 2024 | 1:14 pm

TSLA

Elon Musk, CEO of Tesla Inc. (NASDAQ:TSLA), discussed the potential of lithium batteries and solar energy to power industries sustainably, dismissing concerns about material shortages. He highlighted the rapid growth of battery production and the importance of energy buffering for electrical grids. The conversation follows the discovery of a large lithium reserve in California and Tesla's report on the Powerwall's performance.

Portfolio Pulse from Benzinga Neuro

January 04, 2024 | 1:14 pm

PTON

Peloton and TikTok have announced a partnership to launch 'TikTokFitness Powered by Peloton'. This collaboration will feature select live Peloton classes, an original instructor series, ongoing creator partnerships, class clips, and celebrity collaborations.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:13 pm